UMR-S949 INSERM, Université de Strasbourg, Etablissement Français du Sang-Alsace, 10 rue Spielmann, BP 36, 67065, Strasbourg Cedex, France.
Purinergic Signal. 2011 Sep;7(3):293-303. doi: 10.1007/s11302-011-9247-6. Epub 2011 Jul 27.
Following vessel wall injury, platelets adhere to the exposed subendothelium, become activated and release mediators such as TXA(2) and nucleotides stored at very high concentration in the so-called dense granules. Released nucleotides and other soluble agents act in a positive feedback mechanism to cause further platelet activation and amplify platelet responses induced by agents such as thrombin or collagen. Adenine nucleotides act on platelets through three distinct P2 receptors: two are G protein-coupled ADP receptors, namely the P2Y(1) and P2Y(12) receptor subtypes, while the P2X(1) receptor ligand-gated cation channel is activated by ATP. The P2Y(1) receptor initiates platelet aggregation but is not sufficient for a full platelet aggregation in response to ADP, while the P2Y(12) receptor is responsible for completion of the aggregation to ADP. The latter receptor, the molecular target of the antithrombotic drugs clopidogrel, prasugrel and ticagrelor, is responsible for most of the potentiating effects of ADP when platelets are stimulated by agents such as thrombin, collagen or immune complexes. The P2X(1) receptor is involved in platelet shape change and in activation by collagen under shear conditions. Each of these receptors is coupled to specific signal transduction pathways in response to ADP or ATP and is differentially involved in all the sequential events involved in platelet function and haemostasis. As such, they represent potential targets for antithrombotic drugs.
血管壁损伤后,血小板黏附于暴露的内皮下层,被激活并释放如血栓素 A2(TXA2)和核苷酸等介质,这些介质储存在所谓的致密颗粒中,浓度非常高。释放的核苷酸和其他可溶性物质通过正反馈机制作用,导致进一步的血小板激活,并放大由凝血酶或胶原等物质诱导的血小板反应。腺嘌呤核苷酸通过三种不同的 P2 受体作用于血小板:两种是 G 蛋白偶联的 ADP 受体,即 P2Y1 和 P2Y12 受体亚型,而 P2X1 受体配体门控阳离子通道则被 ATP 激活。P2Y1 受体启动血小板聚集,但不足以完全激活 ADP 诱导的血小板聚集,而 P2Y12 受体负责完成 ADP 诱导的聚集。后者受体是抗血栓药物氯吡格雷、普拉格雷和替格瑞洛的分子靶点,在凝血酶、胶原或免疫复合物等物质刺激血小板时,对 ADP 的大部分增强作用负责。P2X1 受体参与血小板在切变条件下的形状变化和胶原激活。这些受体中的每一个都与特定的信号转导途径偶联,以响应 ADP 或 ATP,并在血小板功能和止血过程中涉及的所有连续事件中发挥不同的作用。因此,它们代表了抗血栓药物的潜在靶点。